Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion

Author(s): Sarah Shirley, Alexandre Morizot and Olivier MicheauPages 311-323 (13) Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present...

Read More

Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women

Author(s): Zsuzsanna SubaPages 154-167 (14) Abstract: Literary data suggest apparently ambiguous interaction between menopausal status and obesity-associated breast cancer risk based on the principle of the carcinogenic capacity of estrogen. Before menopause, breast cancer incidence is relatively low and adiposity is erroneously regarded as a protective factor against this tumor conferred by the obesity associated defective estrogen-synthesis. By contrast, in postmenopausal cases, obesity presents a strong risk factor for breast cancer being...

Read More

Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery

Author(s): Zsuzsanna SubaPages 1-13 (13) Abstract: Background. Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures. Objective. Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration does not work as might be expected; our therapeutic practice requires thorough rethinking. Method. Published long-term therapeutic results on breast cancer...

Read More

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Author(s): Li Huang, Rongzhang He, Weihao Luo, Yuan-Shan Zhu, Jia Li, Tan Tan, Xi Zhang, Zheng Hu and Dixian LuoPages 184-196 (13) Abstract: Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic...

Read More